NCT07434869Recruiting
Plasma and Radiologic Biomarkers of Response to ECP in Lung Transplant Recipients With CLAD
Source: ClinicalTrials.gov · Last updated 14 Jul 2026
Brief summary (registry, in English)
This study is for people who have had a lung transplant and developed a condition called chronic lung allograft dysfunction (CLAD), which is a type of chronic rejection. Doctors often treat CLAD with a procedure called extracorporeal photopheresis (ECP), but it can take up to six months to know if the treatment is working. The goal of the study is to find early signs (biomarkers) that show whether ECP is helping, so patients can get the right care sooner. For participants in the study, small blood samples will be collected at three points during ECP treatment and, for some participants, two MRI scans of the lungs will be performed-one before starting ECP and one after finishing treatment. The MRI uses a safe contrast dye to help us see changes in lung blood flow and tissue. Investigators will also look at certain immune cells in the blood. This is not a study of a new drug or treatment-participants will receive the same ECP therapy their doctor already recommended. The study will help researchers understand how ECP works and identify markers that predict who benefits most. There is no direct benefit to participants, but participation may help improve care for future lung transplant patients.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 25 (estimated)
- First submitted
- 20 Feb 2026
- Start date
- 25 Mar 2026
- Primary completion date
- 28 Feb 2030
- Lead sponsor
- Brian Keller
- NCT number
- NCT07434869
What you commit to
- Study type: Observational
- Planned participants: 25
- From 25 Mar 2026 to the primary completion date, 28 Feb 2030
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously received ECP treatment
Other illness
- Contraindications to MRI (for MRI subgroup), including metal implants, claustrophobia, seizure disorder
Lab values
- Known allergy to gadolinium or impaired kidney function (eGFR \<30 ml/min)
Other
- Receipt of anti-thymocyte globulin within 3 months or alemtuzumab within 12 months of ECP initiation
- Pregnant or breastfeeding
Who the study is looking for
- Adults (≥18 years) or pediatric patients (7-17 years) who have had a single or double lung transplant
- Diagnosed with CLAD (any stage) and prescribed ECP therapy
- Ability to provide informed consent (or assent with parental consent for minors)
Age in the registry: 7 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Massachusetts General Hospital Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
| Brigham and Women's Hospital Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
| The Ohio State University -Wexner Medical Center Coordinator of this site? Confirm its status | Columbus | United States | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.